Determination of blood enzyme activity and evaluation of the effectiveness of psychopharmacotherapy in children with schizophrenia spectrum disorders: a pilot study

Determination of blood enzyme activity and evaluation of the effectiveness of psychopharmacotherapy in children with schizophrenia spectrum disorders: a pilot study

 

Authors

 

I.S. Boksha

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

O.V. Shushpanova

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

O.K. Savushkina

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

T.A. Prokhorova

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

E.B. Tereshkina

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

E.A. Vorobyeva

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

G.Sh. Burbaeva

Mental Health Research Center, Russian Academy of Sciences, Moscow, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-4(129)-31-42

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 4 (129):  31-42.

 

Abstract

Background. Schizophrenia spectrum disorders (SSD) in childhood represent a pressing issue in modern child psychiatry. They are characterized by a severe course and are often resistant to psychopharmacotherapy, which particularly complicates the work of clinical psychiatrists. Pharmacological correction of mental disorders in children is the main method of treatment and provides the opportunity for further psychological and pedagogical work and social adaptation of the child. Therefore, its success is extremely important in the rehabilitation of patients and will always remain a sought-after object of scientific research. Recently, the identification of biological markers that help evaluate the effectiveness of psychopharmacotherapy and act as predictors of an individual patient’s response to treatment has become increasingly important. Objective: To study the relationship between platelet and erythrocyte enzyme activity levels and assessments of the effectiveness of psychopharmacotherapy in children with SSD. Materials and Methods. The sample consisted of 30 children hospitalized due to deterioration of their mental state, with diagnoses of schizophrenia (F20.x, n=11) and schizotypal personality disorder (SPD, F21.x, n=19). Clinical and psychopathological assessment of the condition was conducted at two control points (before and after the course of therapy) using individual interviews and the PANSS rating scale. As biological markers, the activity levels of glutamate, glutathione, and energy metabolism enzymes in platelets and erythrocytes were determined only at the first control point. Statistical analysis was performed using the nonparametric analysis modules of the Statistica program (Statsoft 10). Results. In patients with schizophrenia and STD, under the influence of pharmacotherapy, clinical improvement was observed at the 2nd control point, with a slight advantage in the group of patients with STD (p=0.00004) compared to patients with schizophrenia (p=0.003, Wilcoxon test). Statistically significant correlations were found between the activity levels of glutamate, glutathione, and energy metabolism enzymes and (1) the PANSS scores at time point 2: these scores directly correlated with the activity levels of glutathione peroxidase (Spearman R=0.45, p=0.014) and glutathione-S-transferase (R=0.40, p=0.030) and inversely correlated with the activity levels of cytochrome-c oxidase (R=-0.43, p=0.016), as well as (2) with the degree of clinical improvement, i.e., with the reduction in scores on the PANSS and its subscales: the magnitude of reduction in the total score on the PANSS and its subscales inversely correlated with the activity levels of glutamate dehydrogenase (R=-0.43; p=0.018). Conclusion. The statistically significant correlations obtained in this pilot study represent innovative data that are of particular importance in modern psychiatry; however, they require further development and expanded study in larger representative samples. The use of the identified markers as predictors of individual therapeutic response may be used in the future for practical purposes as a routine study to improve the quality of psychopharmacotherapy.

 

Keywords: childhood, schizophrenia, schizotypal disorder, glutamate dehydrogenase, cytochrome-c-oxidase, glutathione peroxidase, glutathione-S-transferase, creatine phosphokinase, platelets, erythrocytes.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Boksha I.S., Shushpanova O.V., Savushkina O.K., Prokhorova T.A., Tereshkina E.B., Vorobyeva E.A., Burbaeva G.Sh. Determination of blood enzyme activity and evaluation of the effectiveness of psychopharmacotherapy in children with schizophrenia spectrum disorders: a pilot study. Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 4 (129): 31-42. https://doi.org/10.26617/1810-3111-2025-4(129)-31-42

 

REFERENCES

  1. Ivanov M, Boksha I, Balakireva E, Klyushnik T. Epidemiological study on the early detection of mental disorders in young children in Russia. Consort Psychiatr. 2022 Dec 28;3(4):18-26. https://doi.org/10.17816/CP208. PMID: 39045580; PMCID: PMC11262077.
  2. Kendhari J, Shankar R, Young-Walker L. A review of childhood-onset schizophrenia. Focus (Am Psychiatr Publ). 2016 Jul;14(3):328-332. https://doi.org/10.1176/appi.focus.20160007. Epub 2016 Jul 8. PMID: 31975813; PMCID: PMC6526799.
  3. Tonge BJ, Testa R, Díaz-Arteche C, Brereton AV, Stephanou K, Pantelis C. Schizotypal disorder in children ‒ A neglected diagnosis. Schizophrenia.Bull Open. 2020;1(1):sgaa048. https://doi.org/10.1093/schizbullopen/sgaa048
  4. Fellowes S. A history of childhood schizophrenia and lessons for autism. Hist Philos Life Sci. 2024 Aug 12;46(3):29. https://doi.org/10.1007/s40656-024-00627-5. PMID: 39133341; PMCID: PMC11319613.
  5. Remberk B, Bogumił B, Bronowska Z, Namysłowska I, Potocki P. Retrospektywna analiza obrazu psychopatologicznego epizodów psychotycznych u hospitalizowanej młodziezy [Retrospective analysis of psychopathological presentation of psychotic episodes in adolescent inpatients]. Psychiatr Pol. 2012 Mar-Apr;46(2):177-88. Polish. PMID: 23214389.
  6. Barneveld PS, Pieterse J, de Sonneville L, van Rijn S, Lahuis B, van Engeland H, Swaab H. Overlap of autistic and schizotypal traits in adolescents with autism spectrum disorders. Schizophr Res. 2011 Mar;126(1-3):231-6. https://doi.org/10.1016/j.schres.2010.09.004. Epub 2010 Oct 8. PMID: 20933368.
  7. Boksha IS, Omel'chenko MA, Savushkina OK, Prokhorova TA, Tereshkina EB, Vorobyeva EA, Burbaeva GS. Links of platelet glutamate and glutathione metabolism with attenuated positive and negative symptoms in depressed patients at clinical high risk for psychosis. Eur Arch Psychiatry Clin Neurosci. 2023 Feb;273(1):157-168. https://doi.org/10.1007/s00406-022-01396-7. Epub 2022 Mar 15. PMID: 35292857.
  8. Savushkina OK, Boksha IS, Omelchenko MA, Tereshkina EB, Prokhorova TA, Vorobyeva EA, Burbaeva GSh. Activity of enzymes of glutamate, energy and glutathione metabolism in the first juvenile depression with attenuated symptoms of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8):136‑144. https://doi.org/10.17116/jnevro2022122081136(in Russian).
  9. Prokhorova TA, Tereshkina EB, Savushkina OK, Boksha IS, Vorobyeva EA, Omelchenko MA, Pomytkin AN, Kaleda VG, Burbaeva GSh. The activity of enzymes of glutathione metabolism in blood cells of patients with a high risk of manifestation of endogenous psychoses and patients with the first psychotic episode. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):47‑54. https://doi.org/10.17116/jnevro201911904147(in Russian).
  10. Fisher HF. L-Glutamate dehydrogenase from bovine liver. Methods Enzymol. 1985;113:16-27. https://doi.org/10.1016/s0076-6879(85)13006-5. PMID: 4088065.
  11. Savushkina OK, Tereshkina EB, Prokhorova TA, Boksha IS, Burminskii DS, Vorobyeva EA, Morozova MA, Burbaeva GS. Platelet glutamate dehydrogenase activity and efficacy of antipsychotic therapy in patients with schizophrenia. J Med Biochem. 2020 Jan 10;39(1):54-59. https://doi.org/10.2478/jomb-2019-0018. PMID: 32549778; PMCID: PMC7282235.
  12. Rustin P, Chretien D, Bourgeron T, Gérard B, Rötig A, Saudubray JM, Munnich A. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994 Jul;228(1):35-51. https://doi.org/10.1016/0009-8981(94)90055-8.PMID: 7955428.
  13. Medical laboratory technologies: a guide to clinical laboratory diagnostics: in 2 volumes / [VV Alekseev et al.]; AI Karpishchenko (ed.). 3rd ed., revised and updated. Vol. 2. Moscow: GEOTAR-Media, 2013:792 (in Russian).
  14. Tereshkina EB, Savushkina OK, Boksha IS, Prokhorova TA, VorobyevaEA, Omelchenko MA, Pomytkin AN, Kaleda VG, Burbaeva GSh. Glutathione reductase and glutathione-S-transferase in blood cells in schizophrenia and schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):61‑65. https://doi.org/10.17116/jnevro201911902161 (in Russian).
  15. Shushpanova OV. Use of neuroleptic therapy for the treatment of patients with schizophrenia spectrum disorders in children and adolescents. Bulletin of Medical Science. 2024;4(36):5-19. https://doi.org/10.31684/25418475-2024-4-5 (in Russian).
  16. Taylor JH, Bermudez-Gomez J, Zhou M, Gómez O, Ganz-Leary C, Palacios-Ordonez C, Huque ZM, Barzilay R, Goldsmith DR, Gur RE. Immune and oxidative stress biomarkers in pediatric psychosis and psychosis-risk: Meta-analyses and systematic review. Brain Behav Immun. 2024 Mar;117:1-11. https://doi.org/10.1016/j.bbi.2023.12.019. Epub 2023 Dec 21. PMID: 38141839; PMCID: PMC10932921.
  17. Mityukova TA, Dokukina TV, Polulyakh OE, Bogdanovich IP, Korotkevich TV, Zakharevich OYu, Martynenko AI. Serum glutamate in children with autism and other disorders of psycho-speech development. Laboratory Diagnostics. Eastern Europe. 2020;9(4):420-430. https://doi.org/10.34883/PI.2020.9.4.007 (in Russian).
  18. FedorenkoOYu, IvanovaSA, KornetovaEG. The role of gene polymorphism of the dopamine and glutamate systems in the clinical heterogeneity of schizophrenia and the development of antipsychotic-induced side effects. Siberian Herald of Psychiatry and Addiction Psychiatry. 2023;1(118):5-13. https://doi.org/10.26617/1810-3111-2023-1(118)-5-13 (in Russian).